---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-007709"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2023-03-14T23:59:59+00:00"
generated_at: "2026-06-18T03:22:10.843862+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Reneo achieves target enrollment in Phase 2b STRIDE trial of mavodelpar; topline Q4 2023

## Summary
- Target enrollment reached in global STRIDE study for mavodelpar in adult PMM patients.
- STRIDE AHEAD long-term safety trial amended to enroll PMM due to mtDNA and nuclear DNA defects.
- Topline data from STRIDE expected in Q4 2023; marketing applications planned for 2024.
- STRIDE is a randomized, double-blind, placebo-controlled Phase 2b trial of 100 mg mavodelpar daily.

## SEC filing metadata
- accession: 0000950170-23-007709
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2023-03-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000095017023007709/0000950170-23-007709-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000095017023007709/rphm-20230314.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-007709
- JSON: https://secwatch.observer/filing/0000950170-23-007709.json
- Plain text: https://secwatch.observer/filing/0000950170-23-007709.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.